Table 2.

Logistic regression analysis of relapse-free efficacy at 6 months (modified intention to treat population)

	n	Patients relapse-free	Patients relapsed	Comparison with DP alone			Comparison with primaquine plus DP
				Adjusted odds ratio of relapse*	95% CI	p value	Adjusted odds ratio of relapse†	95% CI
DP alone	50	6 (12%)	44 (88%)	..	..	..	..	..
Tafenoquine plus DP	50	11 (22%)	39 (78%)	0·43	0·14–1·35	0·149	4·57	1·75–11·97
Primaquineplus DP	50	26 (52%)	24 (48%)	0·09	0·03–0·29	<0·0001	..	..

Data are n (%) unless stated otherwise. DP=dihydroartemisinin-piperaquine. Model includes terms for battalion and treatment. Patients who did not show initial clearance of Plasmodium vivax parasitemia, take a concomitant medication with antimalarial activity, have a missing day 180 assessment, or have a zero Plasmodium vivax asexual parasite count at baseline were to be excluded from the analysis. No patients met these criteria.

^*An odds ratio <1 represents a smaller chance of relapse compared with DP alone.

^†An odds ratio <1 represents a smaller chance of relapse compared with primaquine plus DP.